Zachary Hunter, PhD

Waldenström's macroglobulinemia
Whole Genome Sequencing
Lymphoma Predisposition

Predoctoral Trainee (previously held)
Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences
Pathology & Laboratory Medicine

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Richardson K, Castillo JJ, Sarosiek SR, Branagan AR, Flynn CA, Meid K, Gustine JN, Liu X, Kofides A, Liu S, Wolf JL, Kacena KA, Patterson CJ, Guerrera ML, Tsakmaklis N, Treon SP, Hunter ZR. Identification of robust predictors for ibrutinib response by multiomics in MYD88-mutated Waldenström macroglobulinemia. Blood Adv. 2024 May 14; 8(9):2133-2137. PMID: 38237078; PMCID: PMC11059321; DOI: 10.1182/bloodadvances.2023012111;
  2. Zhu D, Wang Z, Zhao JJ, Calimeri T, Meng J, Hideshima T, Fulciniti M, Kang Y, Ficarro SB, Tai YT, Hunter Z, McMilin D, Tong H, Mitsiades CS, Wu CJ, Treon SP, Dorfman DM, Pinkus G, Munshi NC, Tassone P, Marto JA, Anderson KC, Carrasco RD. Author Correction: The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells. Nat Med. 2024 Apr; 30(4):1210.View Related Profiles. PMID: 38273148
  3. Castillo JJ, Branagan AR, Sermer D, Flynn CA, Meid K, Little M, Stockman K, White T, Canning A, Guerrera ML, Kofides A, Liu S, Liu X, Richardson K, Tsakmaklis N, Patterson CJ, Hunter ZR, Treon SP, Sarosiek S. Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia. Blood. 2024 Feb 15; 143(7):582-591. PMID: 37971194; PMCID: PMC10873534; DOI: 10.1182/blood.2023022420;
  4. García-Sanz R, Hunter ZR, Poulain S, Varettoni M, Owen RG. New developments in the diagnosis and characterization of Waldenström's macroglobulinemia. Expert Rev Hematol. 2023; 16(11):835-847. PMID: 37905549
  5. Cholujova D, Beke G, Hunter ZR, Hideshima T, Flores L, Zeleznikova T, Harrachova D, Klucar L, Leiba M, Drgona L, Treon SP, Kastritis E, Dorfman DM, Anderson KC, Jakubikova J. Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström macroglobulinemia. Int J Cancer. 2023 May 01; 152(9):1947-1963. PMID: 36533670; PMCID: PMC9992277; DOI: 10.1002/ijc.34405;
  6. Morelli E, Hunter ZR, Fulciniti M, Gullà A, Perrotta ID, Zuccalà V, Federico C, Juli G, Manzoni M, Ronchetti D, Romeo E, Gallo Cantafio ME, Soncini D, Maltese L, Rossi M, Roccaro AM, Cea M, Tassone P, Neri A, Treon SC, Munshi NC, Viglietto G, Amodio N. Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia. Exp Hematol Oncol. 2022 Sep 12; 11(1):54.View Related Profiles. PMID: 36096954; PMCID: PMC9469525; DOI: 10.1186/s40164-022-00305-x;
  7. Munshi M, Liu X, Kofides A, Tsakmaklis N, Guerrera ML, Hunter ZR, Palomba ML, Argyropoulos KV, Patterson CJ, Canning AG, Meid K, Gustine J, Branagan AR, Flynn CA, Sarosiek S, Castillo JJ, Wang J, Buhrlage SJ, Gray NS, Munshi NC, Anderson KC, Treon SP, Yang G. A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas. Blood Adv. 2022 06 14; 6(11):3332-3338.View Related Profiles. PMID: 35255496; PMCID: PMC9198919; DOI: 10.1182/bloodadvances.2021006147;
  8. Gustine JN, Sarosiek S, Flynn CA, Meid K, Leventoff C, White T, Guerrera ML, Xu L, Kofides A, Tsakmaklis N, Munshi M, Demos M, Patterson CJ, Liu X, Yang G, Hunter ZR, Branagan AR, Treon SP, Castillo JJ. Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy. Haematologica. 2022 May 01; 107(5):1163-1171.View Related Profiles. PMID: 34162182; PMCID: PMC9052900; DOI: 10.3324/haematol.2021.279112;
  9. Castillo JJ, Sarosiek SR, Gustine JN, Flynn CA, Leventoff CR, White TP, Meid K, Guerrera ML, Kofides A, Liu X, Munshi M, Tsakmaklis N, Hunter ZR, Patterson CJ, Branagan AR, Treon SP. Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy. Blood Adv. 2022 02 08; 6(3):1015-1024. PMID: 34965304; PMCID: PMC8945307; DOI: 10.1182/bloodadvances.2021006106;
  10. Yang G, Wang J, Tan L, Munshi M, Liu X, Kofides A, Chen JG, Tsakmaklis N, Demos MG, Guerrera ML, Xu L, Hunter ZR, Che J, Patterson CJ, Meid K, Castillo JJ, Munshi NC, Anderson KC, Cameron M, Buhrlage SJ, Gray NS, Treon SP. The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance. Blood. 2021 11 18; 138(20):1966-1979.View Related Profiles. PMID: 34132782; PMCID: PMC8602936; DOI: 10.1182/blood.2021011405;
Showing 10 of 148 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 148 publications over 20 distinct years, with a maximum of 15 publications in 2018 and 2020


Contact for Mentoring:

Hunter's Networks
Click the "See All" links for more information and interactive visualizations
Similar People